Salute e Benessere
Piramal Pharma Limited Announces Results for Q1FY26
said, "
- also delivered good growth during the quarter
- through better procurement strategies and operational excellence initiatives
- at Aurora (Canada) facility with zero observations. Aurora facility specializes in API development and manufacturing
- project at Lexington (US), which specializes in sterile injectable drug products. This should lend impetus to our integrated ADC development and manufacturing program over the medium to long term
- Incomplete and inconsistent recovery in funding for emerging biopharma companies leading to prolonged decision making by the customers and slower growth in early-stage development projects
- Slower growth in Q1FY26 due to phasing of institutional orders. Expect growth to pick up in the remaining part of the financial year
o Slower growth in the key market of US, partly offset by encouraging growth in some ex-US markets
o Received USFDA approval for Digwal (India) facility as Sevoflurane API and finished product manufacturing site for both human and veterinary use
- Lower sales in Q1FY26 due to timing of shipment at the end of June. Growth expected to recover in Q2FY26
- – Initiatives to resolve supply constraints on track. Expect the benefits to accrue from FY2027
- Neoatricon® launched in select EU markets in Q1FY26. Expect to launch in more markets in Q2FY26
- continue to grow strong with 18% YoY growth during Q1FY26. Power Brands contributed to 49% of total PCH sales
o Growth was primarily driven by Little's, i-range, and CIR
o Healthy recovery in growth of i-range from impact of regulator induced price control
- - Added 7 new products in Q1FY26
- 13% of PCH sales in Q1FY26
- sales grew at 41% YoY in Q1FY26, contributing 23% to PCH sales
1.Exceptional items include, one time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023
Piramal Pharma Limited will be hosting a conference call for investors / analysts on
The dial-in details for the call are as under:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.
For more information, visit: Piramal Pharma | LinkedIn
Logo: https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q1fy26-302515192.html